Research collaboration between the team of Professor Antonio Gasbarrini of the Gemelli Hospital and the Asian biotechnology companies, Korea and Dx&Vx
According to the International Diabetes Federation, approximately 537 million adults (20-79 years) are living with diabetes worldwide and 206 million adults in the Western Pacific region, including China, Japanand South Korea have diabetes in 2021.
Studies have shown that Asians are at a higher risk of developing type 2 diabetes than people of European descent, even with a lower BMI. Currently, 60% of the world’s diabetic population is Asian. In addition, the number of obese people has rapidly increased worldwide, with the prevalence of obesity exceeding 50% in many countries. Therefore, the prevention of diabetes and obesity is very important as well as the treatment of diseases.
For these reasons, a clinical study has been initiated with the strong commitment of Chongyoon Lim, Chairman of the Korea Group and Hanmi Pharmaceutical and Chairman of the Korea Biotechnology Industry Organization, and is currently progressing at less than 50%. The novelty of this study is the correlation between the new set of biomarkers from multi-omics data and disease status that could be used to prevent and treat these diseases in the next digital therapy solution.
To develop the digital therapy solution, DxVx (acquired in 2021 by Chongyoon Lim) will participate in this clinical study and develop the digital prevention and treatment solution to improve the symptoms of these metabolic syndromes by modulating the microbiota with the development of new probiotics .